Sanofi and GSK announced a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based Vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology. Collaborating […]
Source
This post first appeared on Fav Store – Herbal Products And News, please read the originial post: here
